13 terminated. 13 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Terminated 13 |
| Phase 2 | 3 | Terminated 3 |
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ATG Plus Low-dose PT-Cy for GVHD Prevention Cyclophosphamid, ATG - Hematologic Malignancy | Phase 3 | Terminated | Peking University People's Hospital | 66 | 2023-11-01 | 2025-06-03 |
| Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Evusheld (tixagevimab+cilgavimab) IM or IV - SARS-CoV-2 Infection | Phase 3 | Terminated | MediMergent, LLC | 550 | 2022-06-03 | 2023-09-08 |
| Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases Supportive Palliative Care, Clinical Management, Best Practice - Hematopoietic and Lymphoid Cell Neoplasm, Non-Neoplastic Hematologic and Lymphocytic Disorder | Phase 2 / Phase 3 | Terminated | Fred Hutchinson Cancer Center | 458 | 2019-08-15 | 2026-01-12 |
| Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Terminated | Kiadis Pharma | 63 | 2017-11-29 | 2022-05-24 |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 311 | 2014-02-01 | 2021-11-18 |
| Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 327 | 2013-01-01 | 2020-09-29 |
| Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis SAR302503, Placebo - Hematopoietic Neoplasm | Phase 3 | Terminated | Bristol-Myers Squibb | 289 | 2011-12-31 | 2026-08-11 |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor Donor lymphocyte preparation depleted of host functional alloreactive T-cells - Myeloid Leukemia, Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Kiadis Pharma | 40 | 2009-08-01 | 2021-06-14 |
| Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) Hydroxyurea, Phlebotomy - Polycythemia Vera | Phase 3 | Terminated | Consorzio Mario Negri Sud | 365 | 2008-05-01 | 2012-07-20 |
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Imatinib, Nilotinib (AMN107) - Myelogenous Leukemia | Phase 3 | Terminated | Novartis Pharmaceuticals | 6 | 2007-10-01 | 2011-11-07 |
| Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients heparin, concentrated citrate - Hematological Malignancies, Bacteremia | Phase 3 | Terminated | Maastricht University Medical Center | 212 | 2006-07-01 | 2013-03-29 |
| Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) zoledronic acid, dexamethasone, thalidomide - Multiple Myeloma | Phase 3 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 90 | 2003-06-01 | 2014-04-17 |
| Stem Cell Transplantation for Hematological Malignancies Stem Cell Transplant, Busulfan, Cyclophosphamide - Leukemia, Lymphocytic, Acute, AML | Phase 2 / Phase 3 | Terminated | Masonic Cancer Center, University of Minnesota | 11 | 2000-06-07 | 2017-12-05 |
Bone Marrow Diseases (3) · Myeloproliferative Disorders (3) · Polycythemia Vera (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Anemia (2) · Graft vs Host Disease (2) · Hematologic Diseases (2) · Leukemia, Myeloid (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Primary Myelofibrosis (2) · Splenomegaly (2) · Thrombocythemia, Essential (2) · Thrombocytopenia (2)
Hemic and Lymphatic Diseases (13) · Neoplasms (13) · Neoplasms by Site (13) · Hematologic Diseases (11) · Neoplasms by Histologic Type (5) · Cardiovascular Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphoproliferative Disorders (4) · Pathological Conditions, Signs and Symptoms (4) · Vascular Diseases (4) · Bone Marrow Diseases (3) · Bone Marrow Neoplasms (3) · Hemorrhagic Disorders (3)
Cyclophosphamide (3) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (2) · Stem Cell Transplantation (2) · Antilymphocyte Serum (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Calcium Dobesilate (1) · Dexamethasone (1) · Doxorubicin (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Heparin (1) · Hydroxyurea (1) · Imatinib Mesylate (1) · Melphalan (1)
CTI BioPharma (2) · Kiadis Pharma (2) · Bristol-Myers Squibb (1) · Consorzio Mario Negri Sud (1) · Fred Hutchinson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Maastricht University Medical Center (1) · Masonic Cancer Center, University of Minnesota (1) · MediMergent, LLC (1) · Novartis Pharmaceuticals (1) · Peking University People's Hospital (1)
United States (10) · Belgium (6) · Germany (6) · Italy (6) · Netherlands (5) · United Kingdom (5) · Australia (4) · Canada (4) · France (4) · Czechia (3) · Hungary (3) · Russia (3) · Spain (3) · Brazil (2) · Israel (2)
Andrea Velardi, MD (1) · Beth Ziemba (1) · Denis Claude Roy, Prof MD (1) · Denis-Claude Roy, MD (1) · Harry Schouten, MD (1) · Katy Rezvani, MD PhD (1) · Margaret MacMillan, MD (1) · Melissa Alsina, MD (1) · Mohamed Sorror, MD, MSc (1) · Ralph Boccia, MD (1) · Simran Singh (1) · Stephan Mielke, MD (1) · Stephan Mielke, Prof MD (1)
PMID 33275766, PMID 23216616, PMID 24472814, PMID 26181658, PMID 34551507, PMID 39400386, PMID 40534493, PMID 42316774
2016 (1), R01CA227092 (1)